Innate Pharma S.A. (IPHA) PT Lowered to $12 at Citi
Tweet
Share
E-mailGet Alerts IPHA Hot Sheet
Price: $2.40 -2.44%
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz lowered the price target on Innate Pharma S.A. (NASDAQ: IPHA) to $12.00 (from $16.00) while maintaining a Buy rating.
You May Also Be Interested In
- Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist Securities
- Zhongji Innolight Co Ltd (300308:CH) PT Raised to RMB223.80 at HSBC
- Teradyne (TER) PT Raised to $125 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
